Riikka Lahtio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Riikka Lahtio has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Anne Kalela
Department of Medical Biochemistry, University of Tampere Medical School, Tampere, Finland
1 shared publication - Marja-Leena Kortelainen
Department of Forensic Medicine, University of Oulu, Oulu, Finland
1 shared publication - Seppo T. Nikkari
Department of Medical Biochemistry, University of Tampere Medical School and Fimlab laboratories, Tampere, Finland
1 shared publication - Tarja Kunnas
Department of Medical Biochemistry, University of Tampere Medical School, Tampere, Finland
1 shared publication
Latest Publications
- Open Access
- 1 January 2009
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 8 (1) , 43
Gln27Glu variant of Beta2-adrenoceptor gene affects male type fat accumulation in women
The β2-adrenergic receptor (BAR2) is the main lipolytic receptor in white human adipose tissue. There is a functional glutamine 27 glutamic acid (Gln27Glu, rs 1042714) polymorphism in its gene, which has been variably associated with body mass index. This gene variant may be associated with male-type adiposity in women and thus increased cardiovascular risk. We investigated whether the BAR2 Gln27Glu polymorphism is associated with visceral fat and coronary intima thickness in women. The amount of mesenteric and omental fat was directly measured and anthropometric measurements were done from 112 forensic autopsy cases of women aged 15 to 49 years. The thickness of the coronary intima, which reflects the severity of atherosclerosis, was measured by computerized image analysis. The BAR2 Gln27Glu polymorphism was determined by polymerase chain reaction. We found that the amount of visceral fat was significantly higher in women with the Glu allele (689 ± 555 g) compared to Gln/Gln homozygotes (481 ± 392 g, P = 0.023). The waist-hip ratio also tended to be higher in women with the Glu allele compared to Gln/Gln homozygotes (p = 0.050). There were no statistically significant differences between the genotype groups in BMI or the thickness of coronary intima. The Glu allele of the BAR2 gene may be a risk factor for visceral fat accumulation in young to middle-aged women. However, this polymorphism was not associated with preclinical atherosclerosis.
- 1 January 2009
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 8 (1) , 43
Open AccessGln27Glu variant of Beta2-adrenoceptor gene affects male type fat accumulation in women
The β2-adrenergic receptor (BAR2) is the main lipolytic receptor in white human adipose tissue. There is a functional glutamine 27 glutamic acid (Gln27Glu, rs 1042714) polymorphism in its gene, which has been variably associated with body mass index. This gene variant may be associated with male-type adiposity in women and thus increased cardiovascular risk. We investigated whether the BAR2 Gln27Glu polymorphism is associated with visceral fat and coronary intima thickness in women. The amount of mesenteric and omental fat was directly measured and anthropometric measurements were done from 112 forensic autopsy cases of women aged 15 to 49 years. The thickness of the coronary intima, which reflects the severity of atherosclerosis, was measured by computerized image analysis. The BAR2 Gln27Glu polymorphism was determined by polymerase chain reaction. We found that the amount of visceral fat was significantly higher in women with the Glu allele (689 ± 555 g) compared to Gln/Gln homozygotes (481 ± 392 g, P = 0.023). The waist-hip ratio also tended to be higher in women with the Glu allele compared to Gln/Gln homozygotes (p = 0.050). There were no statistically significant differences between the genotype groups in BMI or the thickness of coronary intima. The Glu allele of the BAR2 gene may be a risk factor for visceral fat accumulation in young to middle-aged women. However, this polymorphism was not associated with preclinical atherosclerosis.